Holen Sie sich die Stockscreener-App
2.26
0.44%
0.010
Handel nachbörslich:
2.33
0.07
+3.10%
Schlusskurs vom Vortag:
$2.25
Offen:
$2.26
24-Stunden-Volumen:
300.43K
Relative Volume:
0.35
Marktkapitalisierung:
$240.50M
Einnahmen:
$45.44M
Nettoeinkommen (Verlust:
$-35.43M
KGV:
-6.6471
EPS:
-0.34
Netto-Cashflow:
$-25.39M
1W Leistung:
+7.62%
1M Leistung:
+2.73%
6M Leistung:
-51.71%
1J Leistung:
-52.82%
1-Tages-Spanne:
$2.26
$2.305
1-Wochen-Bereich:
$2.12
$2.37
52-Wochen-Spanne:
$2.00
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Vergleichen Sie MXCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.26 | 239.22M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
126.35 | 220.16B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.84 | 157.03B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
400.69 | 154.21B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.97 | 119.08B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.49 | 46.93B | 5.69B | 4.15B | 623.10M | 6.95 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-22 | Eingeleitet | Stephens | Overweight |
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
Leading vs lagging indicators on MaxCyte Inc. performanceFree Access to Real-Time Trade Insights - Newser
New York State Common Retirement Fund Raises Stock Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
What is the dividend policy of MaxCyte Inc. stockGet daily updates on promising stocks - jammulinksnews.com
Is MaxCyte Inc. a growth stock or a value stockAchieve breakthrough investment performance - jammulinksnews.com
What institutional investors are buying MaxCyte Inc. stockAchieve breakthrough investment performance - jammulinksnews.com
How does MaxCyte Inc. compare to its industry peersBuild a winning portfolio with smart picks - jammulinksnews.com
Why MaxCyte Inc. stock attracts strong analyst attentionFree Stock Market Beginners Guide - Newser
MaxCyte Inc. Company’s Quarterly Earnings Growth: What the Numbers SayBig Profit Small Risk Alerts - Newser
What makes MaxCyte Inc. stock price move sharplyHigh Return Conservative Stocks - Newser
How MaxCyte Inc. stock performs during market volatilitySmart High Yield Swing Trades - Metal.it
What drives MaxCyte Inc. stock priceHigh-yield investments - PrintWeekIndia
MaxCyte (NASDAQ:MXCT) Research Coverage Started at Stephens - Defense World
What makes MaxCyte Inc. stock attractive to long term investorsRapid growth trajectories - jammulinksnews.com
Is MaxCyte Inc. a good long term investmentHigh-return market picks - PrintWeekIndia
What analysts say about MaxCyte Inc. stockRapid portfolio appreciation - Autocar Professional
MaxCyte Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - Autocar Professional
Published on: 2025-07-23 21:52:41 - Autocar Professional
IWN ETF Implied Analyst Target Price: $198.15 - AInvest
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maxcyte Inc-Aktie (MXCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Soleymannezhad Ali | Chief Commercial Officer |
Mar 18 '25 |
Sale |
3.18 |
1,211 |
3,850 |
59,439 |
| Sandoval David I. | GENERAL COUNSEL |
Mar 18 '25 |
Sale |
3.18 |
353 |
1,122 |
64,219 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Mar 18 '25 |
Sale |
3.18 |
6,939 |
22,061 |
111,811 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
| Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
0.71%
1.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):